FDA rejects ivonescimab for a narrow lung cancer indication

On November 15, 2026, the FDA issued Summit Therapeutics a Complete Response Letter, saying it could not approve ivonescimab with platinum-based chemotherapy for advanced or metastatic non-small cell lung cancer after prior EGFR-targeted treatment.

The FDA’s main concern was that the Phase 3 HARMONi trial did not show a statistically significant improvement in overall survival. Although the treatment delayed cancer progression, the agency said that benefit alone did not establish a favorable benefit-risk profile.

The decision applies to this specific, previously treated EGFR-mutated lung cancer group—not to ivonescimab’s entire development program. Summit and Akeso may continue pursuing other indications and further evidence.

Sources:

US FDA Rejects Summit's China-Originated Lung Cancer Drug

FDA rejects Summit's ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class

FDA rejects lung cancer treatment ivonescimab from ...

US FDA declines to approve Summit lung cancer drug after ...

U.S. FDA rejects Summit's China-originated lung cancer drug

News Details

US FDA Rejects Summit’s China-Originated Lung Cancer Drug

Summit's PD-1xVEGF rejected by FDA in lung cancer

US FDA rejects closely watched lung cancer drug from China

FDA rejects approval of Summit, Akeso's PD-1/VEGF bispecific in lung cancer

FDA rejects Summit, Akeso's ivonescimab in narrow lung ...

FDA won't approve Summit, Akeso's ivonescimab

U.S. rejects China's breakout cancer drug | Aju Press

FDA Rejects Summit Therapeutics' Lung Cancer Drug Application, S

Summit sheds commercial leaders before ivonescimab ...